SERA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sera Prognostics Inc (SERA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has a promising product in the women's health diagnostics space and a 'Buy' rating from Jefferies with a $5 price target, the financial performance is weak, technical indicators are bearish, and there are no strong trading signals or recent positive news catalysts. The stock is better suited for monitoring rather than immediate investment.
The technical indicators for SERA are bearish. The MACD histogram is negative and contracting, RSI is neutral at 23.346, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The current price of $2.29 is below the pivot level of $2.503, with key support at $2.301 and resistance at $2.705.
Jefferies initiated coverage with a 'Buy' rating and a $5 price target, citing the company's flagship product PreTRM, which addresses a $1.6B market opportunity in the U.S. Early traction with Elevance partner and Medicaid pilot programs adds potential long-term growth prospects.
Weak financial performance in Q3 2025, with revenue down 44.83% YoY, net income dropping to -$7.81M, EPS declining by 33.33%, and gross margin plummeting to -156.25%. No recent news or significant insider/hedge fund activity. Bearish technical indicators and no strong trading signals from AI Stock Picker or SwingMax.
In Q3 2025, revenue dropped 44.83% YoY to $16,000, net income fell to -$7.81M (-1.33% YoY), EPS declined to -0.16 (-33.33% YoY), and gross margin dropped significantly to -156.25% (-383.22% YoY). The company is experiencing financial struggles with no clear signs of recovery.
Jefferies initiated coverage with a 'Buy' rating and a $5 price target, highlighting the company's innovative product, PreTRM, and its potential to address a large market opportunity. However, no other recent analyst updates or changes in ratings were noted.
